Research and Development

The great physicist Lord Kelvin famously said: “When you can measure what you are speaking about, and express it in …

A US advisory committee has rejected an investigational compound for type II diabetes sufferers, throwing its future into doubt. Dapagliflozin, …

M&A abounds in the CRO sector with INC completing its purchase of Kendle, inVentiv snappig up Pharmanet and ICON buying …

Pharmafocus presents selected highlights from the American Society of Clinical Oncology’s annual meeting in Chicago, beginning with non-small cell lung …

German biotech Lophius Biosciences has made six senior management appointments ahead of a planned 2012 market entry move. The Regensburg-based …

France has unveiled sweeping changes to how it regulates prescription medicines following the scandal surrounding Servier’s Médiator. Health minister Xavier …

French CRO CiToxLAB has appointed Paul Barrow as director of scientific projects and client consulting. He joins the Evreux-based company, …

Sanofi is poised to move sarilumab into phase III trials for rheumatoid arthritis after the monoclonal antibody showed positive results …

Pharma regulators in the US and Europe have put out separate consultations on issues affecting how medicines are developed. The …

Amgen has teamed up with German biotech Micromet to develop tumour-destroying antibodies in a two-year deal that could net Micromet …

Norwegian cancer drug development company Clavis Pharma has appointed Nicholas Adams as chief business officer. He has more than 23 …

The EMA will start producing monthly adverse event reports for the public as part of its plans to open up …

Paris-based genome engineering specialist Cellectis Therapeutics has appointed Dr Andrew Scharenberg as chief scientific officer. He is an attending physician …

 

Novartis’ novel cancer drug Votubia has reduced the size of SEGA brain tumours in a late-stage trial. Votubia (or everolimus …